The Effects of EECP Therapy on Vascular Function and Hypercholesterolemia to be Presented at ACC.14 in Washington, DC
WESTBURY, N.Y. March 24, 2014 –Vasomedical, Inc. (“Vasomedical”) (OTC BB: VASO), a diversified medical technology company specializing in the design, manufacture and sale of medical devices for non-invasive cardiology – including EECP® Therapy systems, the gold standard of ECP therapy, and ECG Holter and Ambulatory Blood Pressure monitoring products – today announced that an abstract titled “EECP Improves Vascular Function And Status In Hypercholesterolemic Subjects with Subclinical Atherosclerosis” has been selected for presentation at the 63rd Scientific Sessions of the American College of Cardiology (ACC) to be held in Washington, DC from March 29-31, 2014.
The authors from Sun Yat Sen University and the State University of New York at Stony Brook researched the effect of EECP Therapy on vascular markers in patients with hypocholesterolemia, the presence of high levels of cholesterol in their blood, but whose atherosclerosis is in an early stage before any symptoms have been noted, called subclinical atherosclerosis.
The abstract (Poster #155) will be presented on Saturday, March 29, 2014 from 10:00 to 10:45 AM in Hall C of the Walter E. Washington Convention Center.
Using common carotid artery intima-media thickness (CCA-IMT) of greater than 1 mm or the presence of plaque on carotid ultrasound clips and no reported symptoms of coronary artery disease as the selection criteria, the subclinical atherosclerotic subjects were randomized into two groups: the EECP Group which underwent the standard EECP regimen of one hour per day for seven weeks while taking Simvastatin 40 mg and the Control Group, which only took Simvastatin 40 mg every day. The researchers evaluated vascular status and functions using CCA-IMT, flow-mediated dilation (FMD) of the brachial artery and pulse wave velocity (PWV) of the subjects at baseline and after seven weeks.
At the beginning of the study there were no significant differences between the two groups. At the end of the study, the LDL levels of the EECP Group were slightly, though not significantly, less than those of the patients in the control group. However, the study reported that the EECP Group had an 11.63 percent reduction of CCA-IMT and a 39.78 percent increase in FMD, demonstrating significant differences in improvement over those changes reported in the control group.
“As physicians, we are well trained and experienced in understanding diseases and providing effective treatments. Our challenge in the future is also how to prevent or slow down the progression of disease. In this study we wanted to explore the use of EECP Therapy to improve endothelial dysfunction by increasing the shear stress on vessel walls,” stated Dr. William Lawson, Professor, Department of Internal Medicine, and Chief of Cardiology and Director of the Heart Institute at Stony Brook.
He continued, ”This study demonstrated that EECP improves carotid artery wall thickness, the primary marker of early atherosclerosis, and vascular remodeling as well as endothelial function, suggesting that EECP is a possible therapeutic strategy for the prevention of atherosclerotic disease.”
Those wishing to see a live demonstration of EECP Therapy may visit Booth # 3003 in the Expo Hall. Exhibits open Saturday, March 29th through Monday, March 31st at 9:30 AM. The exhibits close Saturday and Sunday at 4:30 PM and 2:30 PM on Monday.
Vasomedical, Inc. is a diversified medical technology company specializing in the manufacture and sale of medical devices and in the domestic sale of diagnostic imaging products. The Company’s main proprietary products are EECP Therapy systems, the gold standard of ECP treatment. The Company operates through three wholly owned subsidiaries: Vasomedical Solutions, Vasomedical Global and VasoHealthcare. Vasomedical Solutions manages and coordinates the design, manufacture and sales of EECP Therapy systems, and other medical equipment operations; Vasomedical Global operates the Company’s China-based subsidiaries; and VasoHealthcare is the operating subsidiary for the exclusive sales representation of GE Healthcare diagnostic imaging products in certain market segments. Additional information is available on the Company's website atwww.vasomedical.com.
Except for historical information contained in this release, the matters discussed are forward-looking statements that involve risks and uncertainties. When used in this release, words such as “anticipates”, “believes”, “could”, “estimates”, “expects”, “may”, “plans”, “potential” and “intends” and similar expressions, as they relate to the Company or its management, identify forward-looking statements. Such forward-looking statements are based on the beliefs of the Company’s management, as well as assumptions made by and information currently available to the Company’s management. Among the factors that could cause actual results to differ materially are the following: the effect of business and economic conditions; the effect of the dramatic changes taking place in the healthcare environment; the impact of competitive procedures and products and their pricing; medical insurance reimbursement policies; unexpected manufacturing or supplier problems; unforeseen difficulties and delays in the conduct of clinical trials and other product development programs; the actions of regulatory authorities and third-party payers in the United States and overseas; uncertainties about the acceptance of a novel therapeutic modality by the medical community; continuation of the GEHC agreement; and the risk factors reported from time to time in the Company’s SEC reports. The Company undertakes no obligation to update forward-looking statements as a result of future events or developments.
Todd Fromer / Garth Russell
KCSA Strategic Communications
212-896-1215 / 212-896-1250
email@example.com / firstname.lastname@example.org Media Contacts:
Samantha Wolf / Andrew Herweg
KCSA Strategic Communications
email@example.com / firstname.lastname@example.org